Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome

Cancer

Volumn 118, Issue 12, 2012, Pages 3182-3190

  Chatterjee, Deyali ^a   Katz, Matthew H ^a   Rashid, Asif ^a   Varadhachary, Gauri R ^a   Wolff, Robert A ^a   Wang, Hua ^a   Lee, Jeffrey E ^a   Pisters, Peter W T ^a   Vauthey, Jean Nicolas ^a   Crane, Christopher ^a   Gomez, Henry F ^a   Abbruzzese, James L ^a   Fleming, Jason B ^a   Wang, Huamin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Pancreatic cancer; Pathologic response; Prognosis; Survival

Indexed keywords

FLUOROPYRIMIDINE; GEMCITABINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENERAL PATHOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM, RESIDUAL; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84861846770     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26651     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Huguet F, Orthuon A, Touboul E, Marseguerra R, Mornex F. Pancreatic cancer [in French]. Cancer Radiother. 2010;14(suppl 1):S94-S102.
3. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9:99-132. (Pubitemid 351611725)
4. Ishikawa O, Ohhigashi H, Sasaki Y, et al. The histopathological effect of preoperative irradiation in adenocarcinoma of the periampullary region [in Japanese]. Nihon Gan Chiryo Gakkai Shi. 1988;23:720-727.
5. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
6. White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214-221. (Pubitemid 40568908)
7. Washington K, Berlin J, Branton P, et al. Protocol for the Examination of Specimens from Patients with Carcinoma of the Exocrine Pancreas. Northfield, IL: College of American Pathologists; 2010.
8. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-3502.
9. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-3495.
10. Edge S, Byrd D, Compton C, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
11. Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004;60:437-443. (Pubitemid 39233462)
12. Estrella JS, Rashid A, Fleming JB, et al. Posttherapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2011; doi:10.1002/cncr.26243.
13. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237-1244. (Pubitemid 46202281)
14. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009;133:633-642.
15. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47:141-146. (Pubitemid 41113116)
16. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773-2780.
17. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003;46:298-304.
18. Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17:1159-1167.
19. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-4422. (Pubitemid 350013847)
20. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31:58-64. (Pubitemid 46036902)